Axiom Therapeutics

Axiom Therapeutics has developed a next-generation covalent drug discovery platform that combines quantum-accurate physics simulations with machine-learning acceleration to design novel small molecule covalent therapeutics for previously undruggable protein targets. The company was co-founded by Ryan Geiser, CEO (Cambr

Based based in London, United Kingdom, Axiom Therapeutics works in health.

Profile

Axiom Therapeutics has developed a next-generation covalent drug discovery platform that combines quantum-accurate physics simulations with machine-learning acceleration to design novel small molecule covalent therapeutics for previously undruggable protein targets. The company was co-founded by Ryan Geiser, CEO (Cambridge PhD in Biophysical Chemistry, Gates Scholar, ex-Lazard), and Chris Haggard, CTO (Cambridge PhD in Computational Chemistry). […]

Within the health space, the company focuses on its core offering rather than a broad product line.

London, United Kingdom is where the company is located.

It is recorded at the Plug and Play accelerated startup stage.

Website: www.axiom-therapeutics.com